The study analyzed that the candidiasis therapeutics pipeline comprises approximately 22 drug candidates in different stages of development.
Matinas Biopharma Holdings, Inc. is using Cochleate technology platform for the development of their drug candidates. The technology platform is a lipid-crystal nano-particle targeted drug delivery system, that offers a drug delivery solution with differentiating and disruptive features including oral availability, multi-organ protection, enhanced safety and targeted delivery to the site of the infection and inflammation along with the ability to effectively penetrate the tissues.
The research found that various companies received many designations from the U.S. Food and Drug Administration (USFDA) for the development of candidiasis therapeutics pipeline. In May 2016, USFDA granted the orphan drug designation to SCY-078 for the treatment of invasive candida infections, including candidemia.
Some of the key players developing drugs for the treatment of candidiasis include Seren Pharmaceuticals, Inc., SCYNEXIS, Inc., Matinas Biopharma Holdings, Inc., and others.